Bausch Health Companies Target of Unusually Large Options Trading (NYSE:BHC)

view original post

Bausch Health Companies Inc. (NYSE:BHCGet Rating) was the recipient of unusually large options trading on Thursday. Stock traders purchased 41,101 put options on the company. This represents an increase of approximately 118% compared to the typical volume of 18,880 put options.

Institutional Investors Weigh In On Bausch Health Companies

A number of hedge funds and other institutional investors have recently made changes to their positions in BHC. Glassman Wealth Services increased its stake in Bausch Health Companies by 71.4% in the fourth quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock valued at $32,000 after acquiring an additional 480 shares during the last quarter. Aviva PLC increased its stake in Bausch Health Companies by 2.2% in the first quarter. Aviva PLC now owns 45,626 shares of the company’s stock valued at $1,044,000 after acquiring an additional 971 shares during the last quarter. Fortis Advisors LLC increased its stake in Bausch Health Companies by 17.3% in the first quarter. Fortis Advisors LLC now owns 6,775 shares of the company’s stock valued at $155,000 after acquiring an additional 1,000 shares during the last quarter. Creative Financial Designs Inc. ADV increased its stake in Bausch Health Companies by 525.0% in the first quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock valued at $29,000 after acquiring an additional 1,050 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Bausch Health Companies by 8.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 15,315 shares of the company’s stock valued at $352,000 after acquiring an additional 1,190 shares during the last quarter. 70.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Stock Down 3.4 %

NYSE BHC opened at $7.38 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.87 and a debt-to-equity ratio of 85.63. Bausch Health Companies has a 1-year low of $4.00 and a 1-year high of $29.58. The company has a 50 day moving average of $6.71 and a 200-day moving average of $12.67. The company has a market cap of $2.67 billion, a price-to-earnings ratio of 61.51, a PEG ratio of 0.12 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BHC. JPMorgan Chase & Co. cut Bausch Health Companies from an “overweight” rating to a “neutral” rating in a report on Thursday, July 28th. Truist Financial cut Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Piper Sandler cut their target price on shares of Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Friday, September 9th. Finally, Royal Bank of Canada raised their target price on shares of Bausch Health Companies from $4.50 to $8.00 and gave the company a “sector perform” rating in a research note on Thursday, September 1st. Six analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.60.

Bausch Health Companies Company Profile

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Featured Articles

Receive News & Ratings for Bausch Health Companies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bausch Health Companies and related companies with MarketBeat.com’s FREE daily email newsletter.